- Home
- GMAB vs PAA Comparison
GMAB vs PAA Comparison
Compare GMAB & PAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PAA
- Stock Information
- Founded
- GMAB 1999
- PAA 1981
- Country
- GMAB Denmark
- PAA United States
- Employees
- GMAB N/A
- PAA N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PAA Natural Gas Distribution
- Sector
- GMAB Health Care
- PAA Energy
- Exchange
- GMAB Nasdaq
- PAA Nasdaq
- Market Cap
- GMAB 13.7B
- PAA 12.1B
- IPO Year
- GMAB N/A
- PAA N/A
- Fundamental
- Price
- GMAB $21.88
- PAA $18.91
- Analyst Decision
- GMAB Buy
- PAA Buy
- Analyst Count
- GMAB 7
- PAA 12
- Target Price
- GMAB $37.80
- PAA $20.55
- AVG Volume (30 Days)
- GMAB 1.5M
- PAA 2.6M
- Earning Date
- GMAB 08-07-2025
- PAA 08-08-2025
- Dividend Yield
- GMAB N/A
- PAA 8.03%
- EPS Growth
- GMAB 276.80
- PAA N/A
- EPS
- GMAB 18.36
- PAA 0.93
- Revenue
- GMAB $3,230,902,140.00
- PAA $50,089,000,000.00
- Revenue This Year
- GMAB $747.74
- PAA N/A
- Revenue Next Year
- GMAB $14.81
- PAA $18.84
- P/E Ratio
- GMAB $1.19
- PAA $20.35
- Revenue Growth
- GMAB 25.43
- PAA 3.56
- 52 Week Low
- GMAB $17.24
- PAA $15.58
- 52 Week High
- GMAB $28.56
- PAA $21.00
- Technical
- Relative Strength Index (RSI)
- GMAB 56.89
- PAA 65.23
- Support Level
- GMAB $21.10
- PAA $18.49
- Resistance Level
- GMAB $21.90
- PAA $18.86
- Average True Range (ATR)
- GMAB 0.39
- PAA 0.32
- MACD
- GMAB 0.11
- PAA 0.00
- Stochastic Oscillator
- GMAB 79.95
- PAA 77.73
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.